VTGN beat EPS expectations by 9.22%
Feb 12, 2026, 11:37 PM
0.00%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
VistaGen Therapeutics (VTGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, VistaGen Therapeutics's actual EPS was -$0.45, beating the estimate of -$0.50 per share, resulting in a 9.22% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.